BioLife Solutions, Inc.

BioLife Solutions, Inc.

BLFSยทNASDAQ

$27.25

-0.87%
HealthcareMedical - Instruments & Supplies

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

At a Glance

Live Snapshot
Market Cap$1.33B
EPS-0.2500
P/E Ratio-109.00
Earnings Date08/06/2026
3Y+26.0%
5Y+100.0%
10Y+1069.0%
3Y-91.0%
5Y-555.0%
10Y+76.0%
3Y-337.0%
5Y+209.0%
10Y-565.0%
BioLife Solutions, Inc.

BioLife Solutions, Inc. Profit Bridge

BLFS ยท NASDAQ
Revenue96.21M
Cost of Goods Sold (34.10M)
Gross Profit62.12M
Operating Expenses (74.25M)
Operating Income-12.13M
Interest Expense (2.71M)
Other Income/Expense49.00K
Pretax Income-12.08M
Income Tax (49.00K)
Net Income-12.13M
Net Income
-12.13M

Profitability Analysis

Gross Margin

64.6%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

-12.6%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-12.6%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

BioLife Solutions, Inc. Income Statement

BLFS โ€ข NASDAQ

BioLife Solutions, Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Jan 2015Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
96.2M
82.3M
75.9M
76.2M
119.2M
48.1M
27.4M
19.7M
11M
8.2M
6.4M
6.2M
8.9M
5.7M
2.8M
2.1M
1.6M
1.3M
972.3K
603.2K
GROSS PROFIT
(34.1M)
(28.6M)
(96.5M)
(29.3M)
(90.3M)
(20.6M)
(8.9M)
(6.2M)
(4.3M)
(3.4M)
(2.6M)
(3.2M)
(5.2M)
(3.4M)
(1.4M)
(1.2M)
(1M)
(770.6K)
(463.1K)
(298.1K)
62.1M
53.7M
46.8M
46.9M
28.8M
27.4M
18.5M
13.5M
6.7M
4.8M
3.8M
3M
3.8M
2.3M
1.4M
856.4K
574.6K
551.9K
509.2K
305.2K
OPERATING INCOME
(74.2M)
(60.8M)
(117.6M)
(52.8M)
(73.3M)
(30.8M)
(18.2M)
(9.9M)
(7.8M)
(9.6M)
(8.8M)
(6.2M)
(4M)
(3.2M)
(2.6M)
(2.3M)
(2.9M)
(3M)
(3.2M)
(1.8M)
(55.4M)
(50.2M)
(56M)
(44.9M)
(48.1M)
(21M)
(14.1M)
(8.6M)
(6.6M)
(7.6M)
(7.5M)
(5.3M)
(3.6M)
(2.8M)
(2.1M)
(1.9M)
(2.4M)
(2.6M)
(2.6M)
(1.7M)
(7.6M)
(7.9M)
(18.8M)
(14.8M)
(11.8M)
(6.7M)
(4.1M)
(1.3M)
(1.2M)
(2M)
(1.4M)
(871.1K)
(487.8K)
(463.6K)
(516.5K)
(318.9K)
(414.5K)
(457.6K)
(413.4K)
(57.3K)
-12.1M
-7.1M
-23.4M
-5.9M
-35.2M
-3.3M
-781K
3.7M
-1.1M
-4.9M
-5M
-3.1M
-285.4K
-942.2K
-1.2M
-1.4M
-2.3M
-2.5M
-2.7M
-1.5M
PRE-TAX INCOME
(2.7M)
(719K)
(1.8M)
(687K)
(485K)
(18K)
(5K)
(5K)
(455K)
(318.4K)
(0.0)
(190.3K)
(742.2K)
(733.4K)
(671K)
(588K)
(488K)
(284.8K)
(138.3K)
(56.5K)
-2.7M
-719K
-1.8M
-687K
-485K
40K
501K
276K
-454K
-316K
21.8K
-169.5K
-798.8K
-812K
-745.4K
-587.8K
-486.9K
-278.4K
12.1M
-42.8K
(11.3M)
(2.7M)
(42.8M)
-6.9M
(13.4M)
(3M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(198.5K)
(0.0)
49K
-4.3M
5M
1.1M
6.1M
5M
-3M
-28.7M
-1.5M
-3.2M
21.8K
-165.1K
-798.8K
-717.3K
-747K
-589.4K
-481K
-311.7K
-138.3K
360.3K
-12.1M
-11.4M
-18.5M
-4.8M
-29M
-1.3M
9.5M
3.3M
-2.5M
-8M
-5M
-3.3M
-1.1M
-1.7M
-2M
-1.4M
-2.8M
-2.5M
-2.9M
-1.1M
NET INCOME
(49K)
-38K
(24K)
-5.2M
-20.1M
-3.3M
-1.5M
(396K)
(0.0)
(1.6M)
(0.0)
(0.0)
(0.0)
-368.0
(0.0)
(3.1K)
-6K
(60.2K)
(0.0)
(0.0)
-12.1M
-20.2M
-66.4M
-139.8M
-8.9M
2.7M
-1.7M
3.3M
-2.5M
-6.9M
-4.2M
-3.2M
-1.1M
-1.7M
-2M
-2M
-2.8M
-2.8M
-2.9M
-1.1M

SEC Filings

BLFS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 03, 2026
June 03, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
10-K/A

10-K/A 2025 FY (Amended)

FY

April 28, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 02, 2026
March 02, 2026
2026
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2026

N/A

January 09, 2026
January 08, 2026
2026
8-K

8-K 2025

N/A

November 17, 2025
November 17, 2025
2025
Showing 1 to 10 of 354 filings